Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL992636 | 0.89 | SLC28A1 (0.45) | P2RY2P2RY4P2RY12 | |
| SCHEMBL992410 | 0.83 | POLA1 (0.44) | POLA1CYP2C19 | |
| SCHEMBL15197939 | 0.83 | P2RY2 (0.48) | P2RY2P2RY4POLA1P2RY12CYP3A4 | |
| SCHEMBL15197944 | 0.76 | P2RY2 (0.52) | P2RY2P2RY4POLA1CYP3A4CYP2C9 | |
| SCHEMBL5566439 | 0.74 | SLC28A1 (0.58) | P2RY2P2RY4P2RY12P2RY1 | |
| SCHEMBL5561796 | 0.74 | SLC28A1 (0.58) | P2RY2P2RY4P2RY12P2RY1 | |
| SCHEMBL5561799 | 0.74 | SLC28A1 (0.58) | P2RY2P2RY4P2RY12P2RY1 | |
| SCHEMBL2984123 | 0.74 | SLC28A1 (0.58) | P2RY2P2RY4P2RY12P2RY1 | |
| SCHEMBL5566443 | 0.74 | SLC28A1 (0.58) | P2RY2P2RY4P2RY12P2RY1 | |
| SCHEMBL5849954 | 0.74 | SLC29A1 (0.54) | P2RY2P2RY4POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385337-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170107511-A1 | OLIGONUCLEOTIDE END CAPS | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9512164-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20120142101-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2011005861-A9 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011005861-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385337-B2 | Oligonucleotide end caps | RNGTT, POLRMT, POLM | P2RY2 1708/4885P2RY4 1485/4885POLA1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.